Premium
Relationship between the transplacental gradients of bupivacaine and alpha 1‐acid glycoprotein.
Author(s) -
Petersen MC,
Moore RG,
Nation RL,
McMeniman W
Publication year - 1981
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1981.tb01321.x
Subject(s) - transplacental , bupivacaine , placenta , umbilical vein , glycoprotein , fetus , chemistry , alpha (finance) , endocrinology , medicine , biochemistry , biology , pregnancy , pharmacology , surgery , in vitro , genetics , construct validity , patient satisfaction
1 The binding of bupivacaine (400 ng/ml) to isolated alpha 1‐acid glycoprotein was studied at two protein concentrations. At 20 mg/100 ml the extent of bupivacaine binding was 31.0 +/‐ 1.8% (mean +/‐ s.d., n = 4), and at a protein concentration of 60 mg/100 ml binding of bupivacaine was 85.8 +/‐ 1.5% (n = 4). 2 Bupivacaine and alpha 1‐acid glycoprotein concentrations were measured in plasma samples collected from a maternal peripheral vein and the umbilical vein at delivery (n = 23). The ratio of the foetal:maternal bupivacaine concentrations ranged from 0.17 to 0.52, while the foetal:maternal ration for alpha 1‐acid glycoprotein concentrations ranged from 0.20 to 0.96. A positive relationship emerged between the two ratios (P less than 0.01). 3 The alpha 1‐acid glycoprotein concentration gradient across the placenta, and interindividual variability in the gradient appear to contribute to the low and variable transplacental bupivacaine concentration ratio observed.